For US Healthcare Professionals

For US Healthcare Professionals

ANTI-VEGF THERAPIES HAVE LAID A STRONG FOUNDATION FOR TREATMENT3-6

The standard of care for nAMD and DME

For 2 decades, advances in first-line treatment for nAMD and DME were based solely on the success of intravitreal anti-VEGF monotherapy.3-6 However, VEGF may not be the only disease driver. As we continue to uncover more about the crucial role elevated levels of VEGF and Ang-2 play in the development and progression of disease, we as a community can continue to push the field forward.1,2,15,18

Medical illustration representing the macular anatomy of late-stage nAMD.
Graph-shaped icon accompanying content about a real-world study of patients with nAMD.

A real-world, retrospective study of patients with nAMD who received anti-VEGF monotherapy (49,485 eyes) showed that 28% of eyes received a mean number of 7.3 injections in the first year and achieved a mean visual acuity gain of only 1 letter.23

A LOOK AT YOUR PATIENTS

When thinking about your own experience, how does the number of injections received in a year impact you and your patients? Do you feel that treatment durability meets real-world needs?

Ang-2=angiopoietin-2; DME=diabetic macular edema; nAMD=neovascular age-related macular degeneration; VEGF=vascular endothelial growth factor.

    • Saharinen P, et al. Nat Rev Drug Discov. 2017;16:635-661. 

      Saharinen P, et al. Nat Rev Drug Discov. 2017;16:635-661. 

    • Fiedler U, et al. Nat Med. 2006;12:235-239. 

      Fiedler U, et al. Nat Med. 2006;12:235-239. 

    • MACUGEN [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2016. 

      MACUGEN [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2016. 

    • LUCENTIS [prescribing information]. South San Francisco, CA: Genentech, Inc; 2018. 

      LUCENTIS [prescribing information]. South San Francisco, CA: Genentech, Inc; 2018. 

    • BEOVU [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2020. 

      BEOVU [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2020. 

    • EYLEA [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2019.

      EYLEA [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2019.

    • Mulligan K, et al. JAMA Ophthalmol. 2020;138(1):40-47.

      Mulligan K, et al. JAMA Ophthalmol. 2020;138(1):40-47.

    • Baumal CR. Am J Manag Care. 2020;26(5 suppl):S103-S111.

      Baumal CR. Am J Manag Care. 2020;26(5 suppl):S103-S111.

    • Kim E, et al. Curr Diab Rep. 2019;19(68):1-10.

      Kim E, et al. Curr Diab Rep. 2019;19(68):1-10.

    • Romero-Aroca P. World J Diabetes. 2011;2(6):98-104.

      Romero-Aroca P. World J Diabetes. 2011;2(6):98-104.

    • Hakanpaa L, et al. Nat Commun. 2015;6:1-12.

      Hakanpaa L, et al. Nat Commun. 2015;6:1-12.

    • Augustin HG, et al. Nat Rev Mol Cell Biol. 2009;10:165-177.

      Augustin HG, et al. Nat Rev Mol Cell Biol. 2009;10:165-177.

    • Nambu H, et al. Gene Ther. 2004;11:865-873.

      Nambu H, et al. Gene Ther. 2004;11:865-873.

    • Mueller SB, et al. J Clin Invest. 2016;126(9):3188-3191.

      Mueller SB, et al. J Clin Invest. 2016;126(9):3188-3191.

    • Bolinger MT, et al. Int J Mol Sci. 2016;17:1-23.

      Bolinger MT, et al. Int J Mol Sci. 2016;17:1-23.

    • Bressler SB. Ophthalmology. 2009;116:S1-S7.

      Bressler SB. Ophthalmology. 2009;116:S1-S7.

    • Scott IU, et al. Diabetes and Ocular Disease: Past, Present, and Future Therapies. 2010. Oxford; New York: Oxford University Press in cooperation with the American Academy of Ophthalmology.

      Scott IU, et al. Diabetes and Ocular Disease: Past, Present, and Future Therapies. 2010. Oxford; New York: Oxford University Press in cooperation with the American Academy of Ophthalmology.

    • Clapp C, et al. Physiol Rev. 2009;89:1177-1215.

      Clapp C, et al. Physiol Rev. 2009;89:1177-1215.

    • Kienast Y, et al. Clin Cancer Res. 2013;19:6730-6740.

      Kienast Y, et al. Clin Cancer Res. 2013;19:6730-6740.

    • Klaassen I, et al. Prog Retin Eye Res. 2013;1-30.

      Klaassen I, et al. Prog Retin Eye Res. 2013;1-30.

    • Bhisitkul RB. Br J Ophthalmol. 2006;90:1542-1547.

      Bhisitkul RB. Br J Ophthalmol. 2006;90:1542-1547.

    • Shibuya M. Genes Cancer. 2011;2:1097-1105.

      Shibuya M. Genes Cancer. 2011;2:1097-1105.

    • Ciulla TA, et al. Ophthalmol Retina. 2020;4:19-30

      Ciulla TA, et al. Ophthalmol Retina. 2020;4:19-30

    • Hahn P, ed. ASRS 2020 Preferences and Trends Membership Survey. American Society of Retina Specialists; 2020.

      Hahn P, ed. ASRS 2020 Preferences and Trends Membership Survey. American Society of Retina Specialists; 2020.

    • Cohen SY, et al. Retina. 2013;33:474-481.

      Cohen SY, et al. Retina. 2013;33:474-481.

    • Holz FG, et al. Br J Ophthalmol. 2015;99:220-226.

      Holz FG, et al. Br J Ophthalmol. 2015;99:220-226.

    • Holekamp NM, et al. Am J Ophthalmol. 2018;191:83-91.

      Holekamp NM, et al. Am J Ophthalmol. 2018;191:83-91.